

Patent

Attorney's Docket No. 0070777-000022

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of	) MAIL STOP: SEQUENCE
Kye-Seong KIM et al.	) Group Art Unit: To be assigned
Application No.: 10/582,915	) Examiner: To be assigned
Filed: June 14, 2006	) Confirmation No.: 7421
For: NOVEL MIRNA MOLECULES ISOLATED FROM HUMAN EMBRYONIC STEM CELL	) ) )

## TRANSMITTAL LETTER FOR RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE LISTING REQUIREMENTS AND PRELIMINARY AMENDMENT

MAIL STOP: SEQUENCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In complete response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed on April 2, 2007, enclosed please find:

- [X] A Response to Notice to Comply with Sequence Listing Requirement and Preliminary Amendment with paper copy of attached substitute Sequence Listing.
- [X] A diskette containing a computer readable version of the substitute Sequence Listing.
- [X] A Declaration Pursuant to 37 C.F.R. §§ 1.821-1.825.
- [X] A copy of the Notice mailed on April 2, 2007.



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
ON 1450
Alexandria, Virginia 22313-1450
www.marto.com

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT		ATTY.	. DOCKET NO.
10/582,915	Kye-Seong Kim	1012679-000123		
	·	INTERN	ATIONAL APP	LICATION NO.
	* · · · · · · · · · · · · · · · · · · ·	PCT/KR04/03308		
21839	1012479-000123	I.A. FILIN	IG DATE	PRIORITY DATE
BUCHANAN, INGERSOLL & ROON POST OFFICE BOX 1404	EY PC SMD	12/15/	2004	12/15/2003
Dequence listing Colo 107	APR 0 4 2007	371 FORM	ALITIES LI	ATION NO. 7421 ETTER
Date Mailed: 04/02/2007	DOCKETED &			

## NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• The paper or compact disc copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). Applicant must provide a substitute paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application OR a substitute computer readable form (CRF) copy of the "Sequence Listing". These two items must be the same. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000. see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web. https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17, 1.20(d) and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

**BUCHANAN INGERSOLL & ROONEY PC** 

Date: May 14, 2007

Christopher L. North, Ph.D. Registration No. 50,433

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620 visit our website at <a href="http://www.uspto.gov/ebc.">http://www.uspto.gov/ebc.</a>

# If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

PAULETTE R KIDWELL

Telephone: (703) 308-9140 EXT 216

# PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/582,915	PCT/KR04/03308	1012679-000123

FORM PCT/DO/EO/922 (371 Formalities Notice)

}





The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number:

Source:

Date Processed by STIC:

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,

2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE <u>CHECKER</u> <u>VERSION 4.4.0 PROGRAM</u>, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1. EFS-Bio (<a href="http://www.uspto.gov/ebc/efs/downloads/documents.htm">httm</a>, EFS Submission User Manual ePAVE)
- 2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
- Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05):
   U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Street,
   Alexandria, VA 22314

Revised 01/10/06





**IFWP** 

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/582,915.

DATE: 06/22/2006

TIME: 13:08:12

Input Set : A:\Sequence Listing.txt
Output Set: N:\CRF4\06222006\J582915.raw

3 <110> APPLICANT: KIM, Kye-Seong

5 <120> TITLE OF INVENTION: Novel miRNA molecules isolated from human embryonic stem cell

7 <130> FILE REFERENCE: OP04-1083

C--> 9 <140> CURRENT APPLICATION NUMBER: US/10/582,915

C--> 9 <141> CURRENT FILING DATE: 2006-06-14

9 <160> NUMBER OF SEQ ID NOS: 99

11 <170> SOFTWARE: KopatentIn 1.71

Does Not Comply

Corrected Diskette Needed

#### ERRORED SEQUENCES

805 <210> SEQ ID NO: 73

806 <211> LENGTH: 23

807 <212> TYPE: RNA

808 <213> ORGANISM: Homo sapiens

810 <400> SEQUENCE: 73

B--> 811
uaagugcuuc cauguuviilg um

1171 <210> SEO ID NO: 99

1172 <211> LENGTH: 72

1173 <212> TYPE: RNA

1174 <213> ORGANISM: Artificial Sequence

1176 <220> FEATURE:

1177 <223> OTHER INFORMATION: miRNA precursor for miR-374

1180 <400> SEQUENCE: 99

1181

s delete

1183

auugucugug u B--> 1187

B--> 1189 1

, ,

S C C

23 EXPLANATION

ON PAJE =

60 ·

72

VARIABLE LOCATION SUMMARY

PATENT APPLICATION: US/10/582,915

DATE: 06/22/2006 TIME: 13:08:13

Input Set : A:\Sequence Listing.txt

Output Set: N:\CRF4\06222006\J582915.raw

Use of n's or Xaa's (NEW RULES): EVYOR EXPLANATION. C Use of n's and/or Xaa's have been detected in the Sequence Listing. Use of <220> to <223> is MANDATORY if n's or Xaa's are present. in <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.

Seq#:73; N Pos. 18,19,22,23

VERIFICATION SUMMARY

PATENT APPLICATION: US/10/582,915

DATE: 06/22/2006 TIME: 13:08:13

Input Set : A:\Sequence Listing.txt
Output Set: N:\CRF4\06222006\J582915.raw

L:9 M:270 C: Current Application Number differs, Replaced Current Application No L:9 M:271 C: Current Filing Date differs, Replaced Current Filing Date L:811 M:340 E: (46) "n" or "Xaa" used: Feature required, for SEQ ID#:73 L:1187 M:254 E: No. of Bases conflict, this line has no nucleotides. M:254 Repeated in SeqNo=99